|
|
|
Elevai Labs Inc (NASDAQ: ELAB) |
|
Elevai Labs Inc
ELAB's Fundamental analysis
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
|
Looking into Elevai Labs Inc growth rates, revenue grew
in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 3109
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.73 %
• More on ELAB's Growth
|
|
Elevai Labs Inc
realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.81 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 0.1.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
• More on ELAB's Valuation
|
|
|
|
|
Elevai Labs Inc
realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 17.81 in trailing twelve-month period. |
| Company |
| - |
|
PE TTM
|
| Industry |
|
- |
|
PE TTM
|
|
Company's Price to Sales ratio is at 0.1.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.18.
Elevai Labs Inc Price to Book Ratio is at 6.45 lower than Industry Avg. of 79.58. and higher than S&P 500 Avg. of 0.01
• More on ELAB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
